Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages

Journal of Immunology

Volumn 194, Issue 9, 2015, Pages 4379-4386

  Shi, Yun ^a,b   Fan, Xuejun ^a   Deng, Hui ^a   Brezski, Randall J ^c   Rycyzyn, Michael ^c   Jordan, Robert E ^c   Strohl, William R ^c   Zou, Quanming ^b   Zhang, Ningyan ^a   An, Zhiqiang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; FC RECEPTOR IV; GAMMA INTERFERON; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CYTOTOXICITY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HETEROGRAFTS; HUMANS; MACROPHAGES; MICE; NEOPLASMS; PHAGOCYTOSIS; RECEPTOR, ERBB-2; RECEPTORS, IGG;

EID: 84928474102     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402891     Document Type: Article

References (39)

1. Shak, S., Herceptin Multinational Investigator Study Group. 1999. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Semin. Oncol. 26(4, Suppl. 12): 71-77.
2. Nagata, Y., K. H. Lan, X. Zhou, M. Tan, F. J. Esteva, A. A. Sahin, K. S. Klos, P. Li, B. P. Monia, N. T. Nguyen, et al. 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
3. Narayan, M., J. A. Wilken, L. N. Harris, A. T. Baron, K. D. Kimbler, and N. J. Maihle. 2009. Trastuzumab-induced HER reprogramming in "resistant"breast carcinoma cells. Cancer Res. 69: 2191-2194.
4. She, Q.-B., S. Chandarlapaty, Q. Ye, J. Lobo, K. M. Haskell, K. R. Leander, D. DeFeo-Jones, H. E. Huber, and N. Rosen. 2008. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3: e3065. Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0003065#pone-0003065-g005.
5. Arnould, L., M. Gelly, F. Penault-Llorca, L. Benoit, F. Bonnetain, C. Migeon, V. Cabaret, V. Fermeaux, P. Bertheau, J. Garnier, et al. 2006. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94: 259-267.
6. Shi, Y., X. Fan, W. Meng, H. Deng, N. Zhang, and Z. An. 2014. Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation. Breast Cancer Res. 16: R33. Available at: http://breast-cancer-research.com/content/16/2/R33.
7. Lin, Z. X., B. Bai, Q. C. Cai, Q. Q. Cai, X. X. Wang, X. Y. Wu, and H. Q. Huang. 2012. High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med. Oncol. 29: 3522-3528.
8. Grugan, K. D., F. L. McCabe, M. Kinder, A. R. Greenplate, B. C. Harman, J. E. Ekert, N. van Rooijen, G. M. Anderson, J. A. Nemeth, W. R. Strohl, et al. 2012. Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function. J. Immunol. 189: 5457-5466.
9. Taskinen, M., M. L. Karjalainen-Lindsberg, H. Nyman, L. M. Eerola, and S. Leppä. 2007. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin. Cancer Res. 13: 5784-5789.
10. Minard-Colin, V., Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder. 2008. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV. Blood 112: 1205-1213.
11. Oflazoglu, E., I. J. Stone, K. A. Gordon, I. S. Grewal, N. van Rooijen, C. L. Law, and H. P. Gerber. 2007. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 110: 4370-4372.
12. Oflazoglu, E., I. J. Stone, L. Brown, K. A. Gordon, N. van Rooijen, M. Jonas, C. L. Law, I. S. Grewal, and H. P. Gerber. 2009. Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40. Br. J. Cancer 100: 113-117.
13. Guilliams, M., P. Bruhns, Y. Saeys, H. Hammad, and B. N. Lambrecht. 2014. The function of Fcγ receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14: 94-108.
14. Leidi, M., E. Gotti, L. Bologna, E. Miranda, M. Rimoldi, A. Sica, M. Roncalli, G. A. Palumbo, M. Introna, and J. Golay. 2009. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than M1 cells in vitro. J. Immunol. 182: 4415-4422.
15. Petricevic, B., J. Laengle, J. Singer, M. Sachet, J. Fazekas, G. Steger, R. Bartsch, E. Jensen-Jarolim, and M. Bergmann. 2013. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J. Transl. Med. 11: 307.
16. Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103: 4005-4010.
17. Weischenfeldt, J., and B. Porse. 2008. Bone marrow-derived macrophages (BMM): isolation and applications. CSH Protoc. 2008: pdb.prot5080. doi: 10.1101/pdb.prot5080.
18. Fan, X., R. J. Brezski, M. Fa, H. Deng, A. Oberholtzer, A. Gonzalez, W. P. Dubinsky, W. R. Strohl, R. E. Jordan, N. Zhang, and Z. An. 2012. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy. Breast Cancer Res. 14: R116. Available at: http://breast-cancer-research.com/content/14/4/R116.
19. Wolterink, S., G. Moldenhauer, M. Fogel, H. Kiefel, M. Pfeifer, S. Lüttgau, R. Gouveia, J. Costa, J. Endell, U. Moebius, and P. Altevogt. 2010. Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res. 70: 2504-2515.
20. Zhang, N., L. Liu, C. D. Dumitru, N. R. Cummings, M. Cukan, Y. Jiang, Y. Li, F. Li, T. Mitchell, M. R. Mallem, et al. 2011. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 3: 289-298.
21. Loisel, S., M. Ohresser, M. Pallardy, D. Daydé, C. Berthou, G. Cartron, and H. Watier. 2007. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit. Rev. Oncol. Hematol. 62: 34-42.
22. Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J. V. Ravetch. 2005. FcγRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23: 41-51.
23. Mechetina, L. V., A. M. Najakshin, B. Y. Alabyev, N. A. Chikaev, and A. V. Taranin. 2002. Identification of CD16-2, a novel mouse receptor homologous to CD16/FcγRIII. Immunogenetics 54: 463-468.
24. Hamaguchi, Y., Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder. 2006. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203: 743-753.
25. Tai, Y. T., H. M. Horton, S. Y. Kong, E. Pong, H. Chen, S. Cemerski, M. J. Bernett, D. H. Nguyen, S. Karki, S. Y. Chu, et al. 2012. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 119: 2074-2082.
26. Cooley, S., L. J. Burns, T. Repka, and J. S. Miller. 1999. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp. Hematol. 27: 1533-1541.
27. Beano, A., E. Signorino, A. Evangelista, D. Brusa, M. Mistrangelo, M. A. Polimeni, R. Spadi, M. Donadio, L. Ciuffreda, and L. Matera. 2008. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J. Transl. Med. 6: 25.
28. Carson, W. E., R. Parihar, M. J. Lindemann, N. Personeni, J. Dierksheide, N. J. Meropol, J. Baselga, and M. A. Caligiuri. 2001. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur. J. Immunol. 31: 3016-3025.
29. Kohrt, H. E., R. Houot, K. Weiskopf, M. J. Goldstein, F. Scheeren, D. Czerwinski, A. D. Colevas, W. K. Weng, M. F. Clarke, R. W. Carlson, et al. 2012. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 122: 1066-1075.
30. Fanger, M. W., and D. V. Erbe. 1992. Fcγ receptors in cancer and infectious disease. Immunol. Res. 11: 203-216.
31. Raghavan, M., and P. J. Bjorkman. 1996. Fc receptors and their interactions with immunoglobulins. Annu. Rev. Cell Dev. Biol. 12: 181-220.
32. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
33. Biburger, M., S. Aschermann, I. Schwab, A. Lux, H. Albert, H. Danzer, M. Woigk, D. Dudziak, and F. Nimmerjahn. 2011. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 35: 932-944.
34. Nimmerjahn, F., A. Lux, H. Albert, M. Woigk, C. Lehmann, D. Dudziak, P. Smith, and J. V. Ravetch. 2010. FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. USA 107: 19396-19401.
35. Takai, T. 2002. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2: 580-592.
36. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
37. Otten, M. A., G. J. van der Bij, S. J. Verbeek, F. Nimmerjahn, J. V. Ravetch, R. H. Beelen, J. G. van de Winkel, and M. van Egmond. 2008. Experimental antibody therapy of liver metastases reveals functional redundancy between FcγRI and FcγRIV. J. Immunol. 181: 6829-6836.
38. Musolino, A., N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, et al. 2008. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26: 1789-1796.
39. Richards, J. O., S. Karki, G. A. Lazar, H. Chen, W. Dang, and J. R. Desjarlais. 2008. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7: 2517-2527.